Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Recommendation of “Hold” from Analysts

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has been assigned an average recommendation of “Hold” from the seven ratings firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a strong buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $4.5333.

ZNTL has been the subject of several recent analyst reports. Wedbush reissued a “neutral” rating and issued a $4.00 price target on shares of Zentalis Pharmaceuticals in a research note on Tuesday, November 11th. Morgan Stanley decreased their target price on shares of Zentalis Pharmaceuticals from $8.00 to $4.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 12th. Wall Street Zen upgraded shares of Zentalis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, November 16th. Leerink Partners restated a “market perform” rating and issued a $2.00 target price on shares of Zentalis Pharmaceuticals in a research report on Tuesday, November 11th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Zentalis Pharmaceuticals in a research report on Wednesday, October 8th.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Catalyst Funds Management Pty Ltd bought a new stake in Zentalis Pharmaceuticals in the second quarter worth about $31,000. Voleon Capital Management LP acquired a new position in shares of Zentalis Pharmaceuticals in the 3rd quarter worth approximately $41,000. Alpine Global Management LLC bought a new stake in shares of Zentalis Pharmaceuticals in the 1st quarter worth approximately $48,000. SG Americas Securities LLC raised its holdings in shares of Zentalis Pharmaceuticals by 35.3% in the 3rd quarter. SG Americas Securities LLC now owns 31,579 shares of the company’s stock worth $48,000 after purchasing an additional 8,236 shares in the last quarter. Finally, Qube Research & Technologies Ltd acquired a new stake in Zentalis Pharmaceuticals during the second quarter valued at approximately $37,000.

Zentalis Pharmaceuticals Trading Up 1.4%

ZNTL opened at $1.41 on Tuesday. The business’s 50 day moving average is $1.48 and its 200-day moving average is $1.46. The stock has a market cap of $101.87 million, a PE ratio of -0.68 and a beta of 1.75. Zentalis Pharmaceuticals has a twelve month low of $1.01 and a twelve month high of $4.00.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.12. As a group, analysts forecast that Zentalis Pharmaceuticals will post -2.42 EPS for the current year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.